NeuroThera Labs Reports Progress in Phase IIb Clinical Trial for Tourette Syndrome

NeuroThera Labs Inc. has made significant progress in its FDA-approved Phase IIb clinical trial for SCI-110, aimed at treating Tourette Syndrome in adults. The company has completed the manufacturing of the investigational product and obtained batch release certification from a European Qualified Person, allowing shipment of trial materials to sites like the Yale Child Study Center and Hannover Medical School. All participating sites are ready to receive the drug supplies, and the company is moving forward with patient enrollment.